Daiichi Sankyo

Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023

By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion

GlobalData’s consensus forecast projects global sales for Enhertu to reach $9.9 billion by 2028

Meiji Seika Pharma had started the late-stage trial among 780 subjects in Japan, with the test period running from November to…

Sun Pharma said it will pay Rs 5.32 crores for the stake

First HER2-low metastatic breast cancer phase-III results for AstraZeneca and Daiichi Sankyo’s Enhertu offer potential to redefine…

Enhertu is a HER2-directed Antibody Drug Conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca for treatment…

The results from the DESTINY-Gastric01 trial showed a 41 per cent improvement in survival and a response rate more than three…

Johnson & Johnson maintained its top position with MCap growth of 7.2 per cent on a QoQ basis

Among the positive performances were Takeda Pharmaceutical and Daiichi Sankyo, which reported more than 100 per cent YoY growth in…